New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
08:41 EDTFINL, FL, LULU, LLY, AUO, FOLD, SONC, ARAYOn The Fly: Pre-market Movers
HIGHER AFTER GUIDANCE: Eli Lilly (LLY), up 1.7%... ALSO HIGHER: Amicus Theraputics (FOLD), up 8.5% after announcing results from Phase 2 study... AU Optronics (AUO), up 4.7% after DigiTimes said company asked to join Amazon supply chain... LOWER AFTER EARNINGS/GUIDANCE: Finish Line (FINL), down 7%... Sonic (SONC), down 5%... Accuray (ARAY), down 25.5%... ALSO LOWER: Foot Locker (FL), down 2% after disappointing results, guidance of peer Finish Line... lululemon (LULU), down 3.9% after downgrade to Neutral at Credit Suisse.
News For FINL;FL;LULU;LLY;AUO;FOLD;SONC;ARAY From The Last 14 Days
Check below for free stories on FINL;FL;LULU;LLY;AUO;FOLD;SONC;ARAY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 10, 2014
15:04 EDTLULULululemon Athletica September 38.5 weekly straddle priced for 7.7% move into Q2
Subscribe for More Information
13:51 EDTLULUlululemon technical commentary ahead of results
Subscribe for More Information
13:25 EDTLULUEarnings Preview: Lululemon could report 'sharply' lower Q2 profit
Subscribe for More Information
07:04 EDTLLYEU grants marketing authorization for Eli Lilly's insulin glargine product
The European Commission granted marketing authorization for Eli Lilly and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above. Lilly/Boehringer Ingelheim's insulin glargine product is the first insulin treatment approved through the European Medicines Agency's biosimilar pathway and the fourth diabetes product approved in the EU from the Lilly-Boehringer Ingelheim alliance. It received a positive recommendation from the Committee for Medicinal Products for Human Use on June 26. The marketing authorisation for the alliance's insulin glargine product is based upon a comprehensive clinical data program. The application included results from pharmacokinetic and pharmacodynamic studies, as well as Phase III studies in patients with type 1 and type 2 diabetes.
September 9, 2014
10:10 EDTFINLOn the Fly: Analyst Upgrade Summary
Subscribe for More Information
09:50 EDTLULULululemon Athletica September volatility increases into Q2
Subscribe for More Information
06:39 EDTLULUlululemon valuation unattractive ahead of results, says Deutsche Bank
Deutsche Bank says lululemon's valuation is unattractive ahead of the company's Q2 results on Thursday morning. Deutsche sees a lack of visibility on when comps will improve and remains cautious on the stock with a Hold rating and $35 price target.
05:30 EDTFINLFinish Line upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
September 8, 2014
07:15 EDTLLYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
07:01 EDTLLYIgnyta names Robert Wild as Chief Scientific Officer
Subscribe for More Information
06:42 EDTLULUlululemon expected to report sharply lower profit, WSJ reports
lululemon is expected to report a sharply lower profit, with analysts expecting a profit of $42.7M in the latest quarter, reports the Wall Street Journal. Investors will be watching for signs the self-inflicted problems are getting resolved after executives said overhauling the company's process will take about 18 months. Reference Link
September 5, 2014
15:21 EDTLULULululemon Athletica September volatility elevated into Q2
Subscribe for More Information
07:49 EDTLULUlululemon challenges persisted in Q2, says Canaccord
Canaccord said the product assortment at lululemon remains stale and the firm sees traffic, product flow, fashion quotient and conversion challenges persisting in Q2. The firm believes the brand remains relevant and has long-term growth opportunities but there are likely to be more fits and starts in the interim. Canaccord keeps its Hold rating and $42 price target on shares of lululemon.
06:34 EDTLULUlululemon estimates lowered ahead of Q2 report at Barclays
Subscribe for More Information
06:33 EDTSONCHundreds arrested following protests over fast food wages, NY Times says
Nearly 500 protestors seeking a $15 per hour wage for fast food workers were arrested in sit-ins yesterday, organizers of the sit-ins told The New York Times. Some home care aides, recruited by the Service Employees International Union, jointed the protests, the newspaper stated. Fast food companies include McDonald's (MCD), Burger King (BKW), Wendy's (WEN), Jack in the Box (JACK), and Sonic Corporation (SONC).Reference Link
06:24 EDTAUOAU Optronics continues to see orders for vehicle displays, DigiTimes says
Subscribe for More Information
September 4, 2014
13:05 EDTLULULululemon Athletica September volatility elevated into Q2
Lululemon Athletica September 12 weekly call option implied volatility is at 72, September is at 56, October is at 46, January is at 37; compared to its 26-week average of 38 according to Track Data, suggesting larger September price movement into the expected release of Q2 on September 11.
10:29 EDTFLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:11 EDTLLYEli Lilly's insulin peglispro for diabetes shows positive Phase III results
Subscribe for More Information
05:52 EDTFLFoot Locker initiated with a Buy at Jefferies
Target $66.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use